{"organizations": [], "uuid": "2bb774594277a4689cc641fd70460d3f04d17725", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-mylan-partners-with-fujifilm-kyowa/brief-mylan-partners-with-fujifilm-kyowa-kirin-biologics-idUSFWN1RO0GF", "country": "US", "domain_rank": 408, "title": "BRIEF-Mylan Partners With Fujifilm Kyowa Kirin Biologics", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-04-11T14:10:00.000+03:00", "replies_count": 0, "uuid": "2bb774594277a4689cc641fd70460d3f04d17725"}, "author": "", "url": "https://www.reuters.com/article/brief-mylan-partners-with-fujifilm-kyowa/brief-mylan-partners-with-fujifilm-kyowa-kirin-biologics-idUSFWN1RO0GF", "ord_in_thread": 0, "title": "BRIEF-Mylan Partners With Fujifilm Kyowa Kirin Biologics", "locations": [], "entities": {"persons": [{"name": "myla", "sentiment": "negative"}], "locations": [{"name": "europe", "sentiment": "none"}, {"name": "humira", "sentiment": "none"}], "organizations": [{"name": "fujifilm kyowa kirin biologics", "sentiment": "negative"}, {"name": "fujifilm kyowa kirin biologics reuters", "sentiment": "negative"}, {"name": "mylan nv - co", "sentiment": "none"}, {"name": "mylan nv -co", "sentiment": "none"}, {"name": "mylan nv", "sentiment": "none"}, {"name": "mylan", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": " 12 AM / Updated 24 minutes ago BRIEF-Mylan Partners With Fujifilm Kyowa Kirin Biologics Reuters Staff \n  Mylan NV: \n* MYLAN PARTNERS WITH FUJIFILM KYOWA KIRIN BIOLOGICS TO COMMERCIALIZE BIOSIMILAR TO HUMIRAÂ® (ADALIMUMAB) \n* MYLAN NV - COMPANIES EXPECT TO RECEIVE A DECISION FROM EMA IN SECOND HALF OF 2018 \n* MYLAN NV - FUJIFILM KYOWA KIRIN BIOLOGICS GRANTS MYLAN AN EXCLUSIVE LICENSE TO COMMERCIALIZE ADALIMUMAB BIOSIMILAR IN EUROPE \n* MYLAN NV - FUJIFILM KYOWA KIRIN BIOLOGICS IS ELIGIBLE TO RECEIVE A SUBSEQUENT COMMERCIALIZATION MILESTONE PAYMENT AND SALES ROYALTIES \n* MYLAN NV - FUJIFILM KYOWA KIRIN BIOLOGICS WILL RECEIVE AN UP-FRONT FEE UNDER DEAL \n* MYLAN NV -CO, FUJIFILM KYOWA KIRIN BIOLOGICS CONTINUE TO NEGOTIATE FOR COMMERCIALIZING PRODUCT IN ADDITIONAL TERRITORIES \n* MYLAN NV - UNDER AGREEMENT TERMS CO TO BE RESPONSIBLE FOR SALES ACTIVITY OF PRODUCT IN EUROPEAN COUNTRIES \n* MYLAN NV - CO, FUJIFILM KYOWA KIRIN BIOLOGICS EXPECT TO RECEIVE DECISION FROM EMA REGARDING MAA FOR PROPOSED BIOSIMILAR TO HUMIRA IN H2 2018 Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-04-11T14:10:00.000+03:00", "crawled": "2018-04-11T14:26:01.001+03:00", "highlightTitle": ""}